Prime Medicine (NASDAQ:PRME) Share Price Breaks Below 50 Day Moving Average – Here’s What Happened

Prime Medicine, Inc. (NASDAQ:PRME – Get Free Report) shares passed below its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $3.74 and traded as low as $3.49. Prime Medicine shares last traded at $3.55, with a volume of 6,127,062 shares traded.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on PRME shares. Weiss Ratings restated a “sell (e+)” rating on shares of Prime Medicine in a research note on Monday, August 31st. HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of Prime Medicine in a research report on Monday, November 16th. Wall Street Zen upgraded Prime Medicine from a “sell” rating to a “hold” rating in a research note on Saturday, October 31st. BMO Capital Markets assumed coverage on Prime Medicine in a research report on Tuesday, August 18th. They issued an “outperform” rating and a $9.00 target price on the stock. Finally, Citigroup reiterated a “market outperform” rating on shares of Prime Medicine in a research note on Friday, September 25th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $7.86.

Read Our Latest Analysis on Prime Medicine

Prime Medicine Trading Down 7.6%

The firm has a 50-day moving average of $3.74 and a 200 day moving average of $3.51. The stock has a market capitalization of $645.82 million, a price-to-earnings ratio of -3.70 and a beta of 2.14.

Prime Medicine (NASDAQ:PRME – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. The business had revenue of $4.21 million for the quarter. Prime Medicine had a negative net margin of 2,497.56% and a negative return on equity of 286.97%. Equities research analysts predict that Prime Medicine, Inc. will post -0.94 EPS for the current fiscal year.

Institutional Trading of Prime Medicine

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Alphabet Inc. bought a new stake in Prime Medicine during the second quarter worth approximately $61,116,000. BlackRock Inc. acquired a new stake in shares of Prime Medicine during the 2nd quarter valued at $35,432,000. Sumitomo Mitsui Trust Group Inc. lifted its position in shares of Prime Medicine by 20.7% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,911,596 shares of the company’s stock valued at $8,895,000 after acquiring an additional 498,612 shares during the last quarter. ADAR1 Capital Management LLC acquired a new stake in shares of Prime Medicine during the 2nd quarter valued at $7,371,000. Finally, Redmile Group LLC bought a new stake in shares of Prime Medicine during the 1st quarter worth $5,536,000. 70.37% of the stock is currently owned by institutional investors.

About Prime Medicine

(Get Free Report)

Prime Medicine is a biotechnology company developing genetic therapies for diseases caused by genetic mutations. Its research focuses on prime editing, a gene-editing technology designed to make targeted changes to DNA, including substitutions, insertions and deletions. The company is working to apply its platform to potential treatments for a range of serious conditions. Its programs are in development, and Prime Medicine does not currently market approved therapies. Founded in 2019, Prime Medicine is based in Cambridge, Massachusetts.

Further Reading

Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.